Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711351 | 0.80 | GAA (0.52) | SMN1; SMN2TSHRMAPTKMT2ARAB9A | |
| SCHEMBL20334992 | 0.76 | MAPK1 (0.78) | MAPK1HSD17B10EPHX2SMN1; SMN2TP53 | |
| SCHEMBL20334993 | 0.76 | MAPK1 (0.78) | MAPK1HSD17B10EPHX2SMN1; SMN2TP53 | |
| SCHEMBL269404 | 0.75 | KYNU (0.62) | TP53 | |
| SCHEMBL29678939 | 0.75 | KYNU (0.62) | TP53 | |
| SCHEMBL4690902 | 0.75 | POLB (0.57) | SMN1; SMN2MAPTKMT2ANPC1RAB9A | |
| SCHEMBL187849 | 0.75 | KYNU (0.62) | TP53 | |
| SCHEMBL4744990 | 0.71 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTNPC1RAB9ALMNA | |
| SCHEMBL19410220 | 0.71 | KYNU (0.57) | TP53 | |
| SCHEMBL11398405 | 0.71 | ATM (0.41) | MAPK1SMN1; SMN2TP53MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086093-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2005-08-10 | — | — | EP | disclosed |
| US-6495566-B2 | POTENT ANTAGONISTS AT THE STRYCHNINE INSENSITIVE GLYCINE BINDING SITE ASSOCIATED WITH THE N-METHYLASPARTIC ACID RECEPTOR COMPLEX | SMITHKLINE BEECHAM CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6413985-B1 | SELECTIVE ANTAGONISTS FOR THE STRYCHNINE INSENSITIVE GLYCINE BINDING SITE ASSOCIATED WITH THE NMDA RECEPTOR COMPLEX. | SMITHKLINE BEECHAM CORPORATION | 2002-07-02 | — | — | US | disclosed |
| US-20020052391-A1 | Tetrahydroquinoline derivatives as glycine antagonists | DI FABIO ROMANO (IT) | 2002-05-02 | — | — | US | disclosed |
| US-6362199-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-1086093-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLAXO WELLCOME S.p.A. (IT) | 2001-03-28 | — | — | EP | disclosed |
| US-6100289-A | ADMINISTERING AN ANALGESIC AMOUNT OF EXCITATORY AMINO ACID ANTAGONIST TO MAMMAL | GLAXO WELLCOME SPA (IT) | 2000-08-08 | — | — | US | disclosed |
| WO-1999064411-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLAXO WELLCOME SPA (IT) | 1999-12-16 | — | — | WO | disclosed |
| US-5962496-A | CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME SPA (IT) | 1999-10-05 | — | — | US | disclosed |
| US-5760059-A | ANTAGONISTS OF EXCITATORY AMINO ACIDS, TREATMENT OF NEURODEGENERATIVE DISEASES | GLAXO WELLCOME SPA (IT) | 1998-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052391-A1 | Tetrahydroquinoline derivatives as glycine antagonists | GLRB, GLRA2, GLRA1 | MAPK1 2795/4885HSD17B10 713/4885EPHX2 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.